Drug intelligence / Profile preview

Ketobest

Development stage: Unknown
Lead developer: Nanjing Lifenergy R&D
Modality: Small Molecules
Administration: Oral

Overview

**Ketobest** is an oral fixed-dose nutritional medicinal product containing ketoanalogues and essential amino acids for nutritional management of chronic kidney disease. Its nitrogen-free ketoanalogues can be transaminated to essential amino acids, supporting protein synthesis while limiting nitrogen intake and urea generation when used with a protein-restricted diet. Goodfellow Pharma markets Ketobest for chronic kidney disease, and the Philippine product is described as a 600 mg film-coated tablet for prevention and treatment of impaired protein metabolism associated with chronic renal insufficiency. ([goodfellowpharma.com](https://goodfellowpharma.com/nephrology))

Brand names: Ketobest
Other names: Compound α-ketoacid tabletsKetoanalogues + essential amino acids

Beyond the preview

Go deeper on Ketobest.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ketobest.

Explore the full profile